ArticleOpen forum infectious diseases2020
Buying Time: The AMR Action Fund and the State of Antibiotic Development in the United States 2020.
Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Antibiotic Resistance and the Return to a Pre-Antibiotic Era: A Critical Narrative Review of a Global Catastrophe.Biomedicines · 2026Review
- Co-infection of Mycobacterium tuberculosis complex and carbapenem-resistant hypervirulent Klebsiella pneumoniae in captive Asiatic black bears: a case report.BMC veterinary research · 2026Article
- AFrontiers in microbiology · 2026Article
- Synergy between ciprofloxacin and temperate phages overcomes therapeutic limitations caused by lysogen formation.Scientific reports · 2025Article
- Current economic and regulatory challenges in developing antibiotics for Gram-negative bacteria.npj antimicrobials and resistance · 2025Review
- Antibiotics re-booted-time to kick back against drug resistance.npj antimicrobials and resistance · 2025Review
- Reserve antibiotics: overcoming limitations of evidence generated from regulatory approval trials.Globalization and health · 2025Review
- New Agents Are Coming, and So Is the Resistance.Antibiotics (Basel, Switzerland) · 2024Review
- A Nonprofit Drug Development Model Is Part of the Antimicrobial Resistance (AMR) Solution.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Fighting Back against Antimicrobial Resistance with Comprehensive Policy and Education: A Narrative Review.Antibiotics (Basel, Switzerland) · 2022Review
- Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.Antimicrobial agents and chemotherapy · 2022Review
- Impact of novel microbial secondary metabolites on the pharma industry.Applied microbiology and biotechnology · 2022Review
- Confidence interval methods for antimicrobial resistance surveillance data.Antimicrobial resistance and infection control · 2021Article
- Structural Dynamics and Perspectives of Vitamin B6 Biosynthesis Enzymes inFrontiers in cellular and infection microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance is a pressing global threat, but companies developing antibiotics are failing. Large pharmaceutical companies recently created the AMR Action Fund, which will invest $1 billion in small antibiotic development companies. To understand the state of antibiotic development in the United States, we conducted a case study of new agents against carbapenem-resistant Gram-negative bacteria. Factors contributing to market failures were slow clinical uptake of drugs despite their effectiveness and safety, relatively small numbers of target infections that are insufficient to support existing drugs economically, and an excess of recently approved and pipeline agents with redundant spectra of activity. The AMR Action Fund will provide an immediate lifeline to companies in danger of failing due to an inability to secure investment, but it will not address issues identified in the case study or fix the antibiotic development model or marketplace. The Fund buys time for reforms to salvage antibiotic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.